257 related articles for article (PubMed ID: 33945534)
21. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness.
Brezina S; Feigl M; Gumpenberger T; Staudinger R; Baierl A; Gsur A
Mutagenesis; 2020 Jul; 35(3):283-290. PubMed ID: 32255470
[TBL] [Abstract][Full Text] [Related]
23. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
Elife; 2020 May; 9():. PubMed ID: 32401198
[TBL] [Abstract][Full Text] [Related]
24. Hierarchical discovery of large-scale and focal copy number alterations in low-coverage cancer genomes.
Khalil AIS; Khyriem C; Chattopadhyay A; Sanyal A
BMC Bioinformatics; 2020 Apr; 21(1):147. PubMed ID: 32299346
[TBL] [Abstract][Full Text] [Related]
25. Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability.
Raynaud F; Mina M; Tavernari D; Ciriello G
PLoS Genet; 2018 Sep; 14(9):e1007669. PubMed ID: 30212491
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?
Ibeawuchi C; Schmidt H; Voss R; Titze U; Abbas M; Neumann J; Eltze E; Hoogland AM; Jenster G; Brandt B; Semjonow A
Int J Mol Sci; 2013 Jun; 14(6):11816-29. PubMed ID: 23736690
[TBL] [Abstract][Full Text] [Related]
27. Analysis of mutational signatures in C. elegans: Implications for cancer genome analysis.
Meier B; Volkova NV; Gerstung M; Gartner A
DNA Repair (Amst); 2020 Nov; 95():102957. PubMed ID: 32980770
[TBL] [Abstract][Full Text] [Related]
28. Hidden Markov models lead to higher resolution maps of mutation signature activity in cancer.
Wojtowicz D; Sason I; Huang X; Kim YA; Leiserson MDM; Przytycka TM; Sharan R
Genome Med; 2019 Jul; 11(1):49. PubMed ID: 31349863
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide copy number analysis reveals candidate gene loci that confer susceptibility to high-grade prostate cancer.
Poniah P; Mohd Zain S; Abdul Razack AH; Kuppusamy S; Karuppayah S; Sian Eng H; Mohamed Z
Urol Oncol; 2017 Sep; 35(9):545.e1-545.e11. PubMed ID: 28527622
[TBL] [Abstract][Full Text] [Related]
30. Clinical and genomic characterization of mutational signatures across human cancers.
Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
[TBL] [Abstract][Full Text] [Related]
31. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
32. Impact of cancer mutational signatures on transcription factor motifs in the human genome.
Yiu Chan CW; Gu Z; Bieg M; Eils R; Herrmann C
BMC Med Genomics; 2019 May; 12(1):64. PubMed ID: 31109337
[TBL] [Abstract][Full Text] [Related]
33. Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G; Goranova TE; De Silva D; Ennis D; Piskorz AM; Eldridge M; Sie D; Lewsley LA; Hanif A; Wilson C; Dowson S; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Paul J; Supernat A; Millan D; Hoyle A; Bryson G; Nourse C; Mincarelli L; Sanchez LN; Ylstra B; Jimenez-Linan M; Moore L; Hofmann O; Markowetz F; McNeish IA; Brenton JD
Nat Genet; 2018 Sep; 50(9):1262-1270. PubMed ID: 30104763
[TBL] [Abstract][Full Text] [Related]
34. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
35. Genomic hallmarks of localized, non-indolent prostate cancer.
Fraser M; Sabelnykova VY; Yamaguchi TN; Heisler LE; Livingstone J; Huang V; Shiah YJ; Yousif F; Lin X; Masella AP; Fox NS; Xie M; Prokopec SD; Berlin A; Lalonde E; Ahmed M; Trudel D; Luo X; Beck TA; Meng A; Zhang J; D'Costa A; Denroche RE; Kong H; Espiritu SM; Chua ML; Wong A; Chong T; Sam M; Johns J; Timms L; Buchner NB; Orain M; Picard V; Hovington H; Murison A; Kron K; Harding NJ; P'ng C; Houlahan KE; Chu KC; Lo B; Nguyen F; Li CH; Sun RX; de Borja R; Cooper CI; Hopkins JF; Govind SK; Fung C; Waggott D; Green J; Haider S; Chan-Seng-Yue MA; Jung E; Wang Z; Bergeron A; Dal Pra A; Lacombe L; Collins CC; Sahinalp C; Lupien M; Fleshner NE; He HH; Fradet Y; Tetu B; van der Kwast T; McPherson JD; Bristow RG; Boutros PC
Nature; 2017 Jan; 541(7637):359-364. PubMed ID: 28068672
[TBL] [Abstract][Full Text] [Related]
36. Application of Nexus copy number software for CNV detection and analysis.
Darvishi K
Curr Protoc Hum Genet; 2010 Apr; Chapter 4():Unit 4.14.1-28. PubMed ID: 20373515
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
38. Pan-cancer analysis of somatic mutations and epigenetic alterations in insulated neighbourhood boundaries.
Pinoli P; Stamoulakatou E; Nguyen AP; Rodríguez Martínez M; Ceri S
PLoS One; 2020; 15(1):e0227180. PubMed ID: 31945090
[TBL] [Abstract][Full Text] [Related]
39. CANCERSIGN: a user-friendly and robust tool for identification and classification of mutational signatures and patterns in cancer genomes.
Bayati M; Rabiee HR; Mehrbod M; Vafaee F; Ebrahimi D; Forrest ARR; Alinejad-Rokny H
Sci Rep; 2020 Jan; 10(1):1286. PubMed ID: 31992766
[TBL] [Abstract][Full Text] [Related]
40. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
